Annals of Surgical Oncology

Journal

Publication Venue For

  • Warm and Welcoming: Is It What We Say or How We Say It?.  27:3581-3582. 2020
  • Race and Gender Disparities in Access to Parathyroidectomy: A Need to Change Processes for Diagnosis and Referral to Surgeons. 2020
  • The Impact of Residential Segregation on Pancreatic Cancer Diagnosis, Treatment, and Mortality 2020
  • Effect of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Malignancy Rates in Thyroid Nodules: How to Counsel Patients on Extent of Surgery.  26:93-97. 2019
  • Select Choices in Benign Breast Disease: An Initiative of the American Society of Breast Surgeons for the American Board of Internal Medicine Choosing Wisely® Campaign.  25:2795-2800. 2018
  • STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro.  25:792-800. 2018
  • Benchmarking the American Society of Breast Surgeon Member Performance for More Than a Million Quality Measure-Patient Encounters.  25:501-511. 2018
  • Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.  24:3674-3682. 2017
  • Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials.  24:2855-2862. 2017
  • Optimizing Outpatient Pain Management After Thyroid and Parathyroid Surgery: A Two-Institution Experience.  24:1951-1957. 2017
  • Breast Malignancies in Children: Presentation, Management, and Survival.  24:1482-1491. 2017
  • Intraoperative Parathyroid Hormone Levels at 5 min Can Identify Multigland Disease.  24:733-738. 2017
  • Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely ®Initiative.  23:3112-3118. 2016
  • Antiplatelet and Anticoagulant Medications Significantly Increase the Risk of Postoperative Hematoma: Review of over 4500 Thyroid and Parathyroid Procedures.  23:2874-2882. 2016
  • Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy.  23:2715-2722. 2016
  • Compromised Outcome of Papillary Thyroid Cancer at Low-Volume Treatment Centers: Practice Makes Perfect?.  23:355-357. 2016
  • [99mTc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial.  22:3708-3715. 2015
  • Clinical and Socioeconomic Factors Influence Treatment Decisions in Graves’ Disease.  22:1196-1199. 2015
  • Outcomes After Subtotal Parathyroidectomy for Primary Hyperparathyroidism due to Hyperplasia: Significance of Whole vs. Partial Gland Remnant.  22:966-971. 2015
  • All Thyroid Ultrasound Evaluations are Not Equal: Sonographers Specialized in Thyroid Cancer Correctly Label Clinical N0 Disease in Well Differentiated Thyroid Cancer.  22:422-428. 2015
  • CaPTHUS Scoring Model in Primary Hyperparathyroidism: Can It Eliminate the Need for ioPTH Testing?.  22:1191-1195. 2015
  • Chasing Calcitonin: Reoperations for Medullary Thyroid Carcinoma.  22:7-8. 2015
  • Justified Follow-Up: A Final Intraoperative Parathyroid Hormone (ioPTH) Over 40 pg/mL is Associated with an Increased Risk of Persistence and Recurrence in Primary Hyperparathyroidism.  22:454-459. 2015
  • Lymph Node Metastases do not Impact Survival in Follicular Variant Papillary Thyroid Cancer.  22:158-163. 2015
  • Preventing Postoperative Hypocalcemia in Patients with Graves Disease: A Prospective Study.  22:952-958. 2015
  • Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Secondary Analysis of TBCRC 017.  22:75-81. 2015
  • The Use of Modified Four-Dimensional Computed Tomography in Patients with Primary Hyperparathyroidism: An Argument for the Abandonment of Routine Sestamibi Single-Positron Emission Computed Tomography (SPECT).  22:139-145. 2015
  • Erratum to: Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival (Annals of Surgical Oncology, DOI: 10.1245/S10434-014-3486-Z).  21:1538. 2014
  • Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma.  21:449-457. 2014
  • Assessment of Erlotinib as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer Patients.  21:4263-4269. 2014
  • Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.  21:1530-1537. 2014
  • Failure of Radioactive Iodine in the Treatment of Hyperthyroidism.  21:4174-4180. 2014
  • Hesperetin Activates the Notch1 Signaling Cascade, Causes Apoptosis, and Induces Cellular Differentiation in Anaplastic Thyroid Cancer.  21:497-504. 2014
  • Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657).  21:2889-2896. 2014
  • Posterior 'superior mesenteric artery first' approach for resection of locally advanced pancreatic cancer.  21:1927-1928. 2014
  • Radioactive iodine remnant uptake after completion thyroidectomy: Not such a complete cancer operation.  21:1379-1383. 2014
  • Silencing of UCHL1 by CpG Promoter Hyper-methylation is Associated with Metastatic Gastroenteropancreatic Well-Differentiated Neuroendocrine (Carcinoid) Tumors.  21:672-679. 2014
  • Surgeon and Staff Radiation Exposure During Radioguided Parathyroidectomy at a High-Volume Institution.  21:3853-3858. 2014
  • Thyroidectomy as primary treatment optimizes body mass index in patients with hyperthyroidism.  21:2303-2309. 2014
  • MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through akt inhibition.  20:3862-3868. 2013
  • Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.  20:3059-3065. 2013
  • Minimal benefit to subsequent intraoperative parathyroid hormone testing after all four glands have been identified.  20:4200-4204. 2013
  • Multigland disease and slower decline in intraoperative PTH characterize mild primary hyperparathyroidism.  20:4205-4211. 2013
  • Presentation, management, and outcomes of hyperparathyroidism in octogenarians and nonagenarians.  20:4195-4199. 2013
  • Comparative evaluation of [99mTc]tilmanocept for sentinel lymph node mapping in breast cancer patients: Results of two phase 3 trials.  20:2590-2599. 2013
  • Parathyroid cryopreservation after parathyroidectomy: A worthwhile practice?.  20:2256-2260. 2013
  • Disparities in pancreas cancer care.  20:2078-2087. 2013
  • Impact of lymph node ratio on survival in papillary thyroid cancer.  20:1906-1911. 2013
  • Doing away with the rule of 10 %.  20:1403-1404. 2013
  • Hereditary medullary thyroid cancer: Age-appropriate thyroidectomy improves disease-free survival.  20:1451-1455. 2013
  • Diversity of stage III melanoma in the era of sentinel lymph node biopsy.  20:956-963. 2013
  • Utility of 111indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.  20:640-645. 2013
  • Sestamibi imaging for primary hyperparathyroidism: The impact of surgeon interpretation and radiologist volume.  19:3827-3831. 2012
  • Surveillance of small rectal carcinoid tumors in the absence of metastatic disease.  19:3486-3490. 2012
  • The role of gender in primary hyperparathyroidism: Same disease, different presentation.  19:2958-2962. 2012
  • Sestamibi-negative patients: To operate or image?.  19:2086-2087. 2012
  • Does the final intraoperative PTH level really have to fall into the normal range to signify cure?.  19:1862-1867. 2012
  • Adverse effects of smoking on postoperative outcomes in cancer patients.  19:1430-1438. 2012
  • Is focused minimally invasive parathyroidectomy appropriate for patients with familial primary hyperparathyroidism?.  19:1264-1268. 2012
  • Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.  19:973-980. 2012
  • Presurgical localization of parathyroid adenomas with magnetic resonance imaging at 3.0 T: An adjunct method to supplement traditional imaging.  19:981-989. 2012
  • Limitations of the ACS NSQIP in thyroid surgery.  18:3529-3530. 2011
  • Does previous head and neck irradiation increase the chance of multigland disease in patients with hyperparathyroidism?.  18:2240-2244. 2011
  • Inadequate cytology of thyroid nodules. Repeat it or live with it.  18:1222-1223. 2011
  • Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.  18:1506-1511. 2011
  • A comparison of the ligasure and harmonic scalpel in thyroid surgery: A single institution review.  18:214-218. 2011
  • Guideline recommended gastric cancer care in the elderly: Insights into the applicability of cancer trials to real world.  18:26-33. 2011
  • What is the added benefit of cervical ultrasound to 99mTc- sestamibi scanning in primary hyperparathyroidism?.  18:2907-2911. 2011
  • 25-Hydroxyvitamin D status does not affect intraoperative parathyroid hormone dynamics in patients with primary hyperparathyroidism.  17:2958-2962. 2010
  • Minimal disease in the sentinel lymph node: How to best measure sentinel node micrometastases to predict risk of additional non-sentinel lymph node disease.  17:2909-2919. 2010
  • Extremity soft tissue sarcoma care in the elderly: Insights into the generalizability of NCI cancer trials.  17:1732-1738. 2010
  • Body mass index does not affect postoperative morbidity and oncologic outcomes of total mesorectal excision for rectal adenocarcinoma.  17:1606-1613. 2010
  • Factors associated with false-negative sentinel lymph node biopsy in melanoma patients.  17:709-717. 2010
  • Utility of intraoperative PTH for primary hyperparathyroidism due to multigland disease.  16:3450-3454. 2009
  • Papillary thyroid microcarcinomas: Big decisions for a small tumor.  16:3132-3139. 2009
  • Inhibition of phosphatidylinositol 3-kinase/akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors.  16:2936-2942. 2009
  • Disparities in gastric cancer outcomes among Asian ethnicities in the USA.  16:2433-2441. 2009
  • Combination therapy with histone deacetylase inhibitors and lithium chloride: A novel treatment for carcinoid tumors.  16:481-486. 2009
  • Older age and larger tumor size predict malignancy in Hürthle cell neoplasms of the thyroid.  15:2842-2846. 2008
  • Suberoyl bishydroxamic acid activates Notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.  15:2600-2605. 2008
  • The influence of surgical approach on quality of life after parathyroid surgery.  15:1559-1565. 2008
  • The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma.  15:900-905. 2008
  • Author reply [2].  15:380-381. 2008
  • Isolated adrenal mass in patients with a history of cancer: Remember pheochromocytoma.  14:2358-2362. 2007
  • The negative sestamibi scan: Is a minimally invasive parathyroidectomy still possible?.  14:2363-2366. 2007
  • Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.  14:2150-2158. 2007
  • Local/cervical block anesthesia versus general anesthesia for minimally invasive parathyroidectomy: What are the advantages?.  14:744-749. 2007
  • Radioguided parathyroidectomy in patients with familial hyperparathyroidism.  14:739-743. 2007
  • Characteristics and treatment of metaplastic breast cancer: Analysis of 892 cases from the national cancer data base.  14:166-173. 2007
  • Is tumor size the best predictor of outcome for papillary thyroid cancer?.  13:1524-1528. 2006
  • Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.  13:1145-1155. 2006
  • Fine-needle aspiration optimizes surgical management in patients with thyroid cancer.  13:859-863. 2006
  • Trends in hospital and surgeon volume and operative mortality for cancer surgery.  13:851-858. 2006
  • Long-term outcomes in patients with calciphylaxis from hyperparathyroidism.  13:96-102. 2006
  • Are minimally invasive techniques for ablation of breast cancer ready for "prime time"?.  11:115-116. 2004
  • The utility of frozen section evaluation for follicular thyroid lesions.  11:94-98. 2004
  • Expression of p53 and proliferation index as prognostic factors in gastrointestinal sarcomas.  10:190-195. 2003
  • Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma.  10:839-851. 2003
  • Annals of surgical oncology impact factor/rating has dramatically increased..  10:1-3. 2003
  • The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined..  10:65-71. 2003
  • Long-term complications of breast-conservation therapy: Can the incidence be reduced?.  9:524-525. 2002
  • Editorial commentary on scientific fraud.  9:419-420. 2002
  • Palliative thyroidectomy for malignant lymphoma of the thyroid.  9:907-911. 2002
  • Primary thyroid lymphoma: Can the diagnosis be made solely by fine-needle aspiration?.  9:298-302. 2002
  • Utilization of sentinel lymph node mapping to determine pathologic outcomes for patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.  9:217-219. 2002
  • Sentinel node biopsy for cutaneous melanoma in the head and neck.  8:716-719. 2001
  • Sentinel node biopsy for cutaneous melanoma in the head and neck..  8:716-719. 2001
  • Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas..  8:101-108. 2001
  • Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas.  8:101-108. 2001
  • Multimodality treatment of merkel cell carcinoma: Case series and literature review of 1024 cases.  8:204-208. 2001
  • Clinicopathological characteristics of gastric carcinoma in young and elderly patients: A comparative study.  7:515-519. 2000
  • Extended lymph node dissection in gastric cancer: If a benefit exists, can it ever be proven?.  7:715-716. 2000
  • Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm).  7:87-97. 2000
  • Current status of endocrine therapy for advanced breast cancer.  6. 1999
  • Future directions in endocrine treatment of advanced breast cancer.  6. 1999
  • Role of new endocrine therapies in the treatment of advanced breast cancer: Introduction.  6. 1999
  • Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer.  6. 1999
  • Refining the optimal technical approach for sentinel node localization in breast cancer patients.  6:418-419. 1999
  • Microstaging of sentinel lymph nodes.  6:15-16. 1999
  • Surgical oncology fellowship: Viable pathway to academic surgery?.  6:542-545. 1999
  • The 1999 James Ewing lecture: In pursuit of molecules of oncogenesis and neoplastic therapy.  6:528-541. 1999
  • Molecular oncogene markers and their significance in cutaneous malignant melanoma.  5:253-260. 1998
  • Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells.  5:279-286. 1998
  • Indications for axillary dissection in T1 breast cancer.  5:4-8. 1998
  • Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas.  5:48-53. 1998
  • Role of axillary lymph node dissection after tumor downstaging.  5:665-666. 1998
  • Superficial extremity soft tissue sarcoma: An analysis of prognostic factors.  5:41-47. 1998
  • Core needle biopsy for diagnosis of extremity soft tissue sarcoma.  4:425-431. 1997
  • Optimal surgical treatment of invasive lobular carcinoma of the breast.  4:545-550. 1997
  • The society at a crossroads: Milestones and imperatives for cancer clinical trials.  4:523-539. 1997
  • Topographic genotyping of colorectal carcinoma: From a molecular carcinogenesis model to clinical relevance.  4:269-278. 1997
  • Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial..  3:110-117. 1996
  • Local recurrence in malignant melanoma: Long-term results of the multiinstitutional randomized surgical trial.  3:446-452. 1996
  • The effect of blood transfusion on tumor growth in Sarcoma-Bearing rats.  3:74-79. 1996
  • Malignant potential in intestinal juvenile polyposis syndromes.  2:386-391. 1995
  • Insurance coverage of patients with breast cancer in the 1991 Commission on Cancer patient care evaluation study.  1:462-467. 1994
  • Effect of perioperative blood transfusion on recurrence and survival in 232 primary high-grade extremity sarcoma patients.  1:189-197. 1994
  • What is a surgical oncologist?.  1:2-4. 1994
  • International Standard Serial Number (issn)

  • 1068-9265
  • Electronic International Standard Serial Number (eissn)

  • 1534-4681